Literature DB >> 19015642

Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH.

Marwa Mahmoud1, Gillian M Borthwick, Alison A Hislop, Helen M Arthur.   

Abstract

Arteriovenous malformations (AVMs) are direct connections between arteries and veins associated with loss of the intervening capillary bed. In the lungs, pulmonary AVMs can result in right to left shunts and severe cyanosis and dyspnoea. However, the cellular and molecular mechanisms underlying AVM formation are poorly understood. One important clue comes from the fact that pulmonary AVMs frequently occur in the familial disease hereditary haemorrhagic telangiectasia (HHT), which is associated with mutations in one of two receptors involved in transforming growth factor-beta family signalling, either endoglin (ENG) or activin receptor-like kinase 1 (ACVRL1, also known as ALK1). To elucidate the potential link between ENG or ACVRL1 deficiency and AVM formation in HHT, we performed a comprehensive study of Acvrl1 and Eng expression in wild-type and Eng-deficient (Eng+/-) mouse lungs using a combination of immunohistochemistry and RT-PCR from laser-microdissected arteries, veins and capillaries. We found that Eng and Acvrl1 have distinct expression profiles in the pulmonary vasculature and are only co-expressed in the distal (pre-capillary) arteries, distal veins and capillaries, consistent with the tendency for pulmonary AVMs to form in the distal pulmonary vessels in HHT. Downstream pSmad1/5/8 activity was found in the distal arteries and was specifically reduced in Eng+/- mice, consistent with previous in vitro data showing that Eng promotes Acvrl1-mediated Smad1/5/8 phosphorylation. Eng was more widely expressed than Acvrl1 in the lungs, as Eng alone was found in pulmonary veins, potentially explaining the increased frequency of AVMs in HHT1 patients. Furthermore, the association of ACVRL1 mutations with a second vascular disease, familial pulmonary artery hypertension, underlines the importance of ACVRL1 expression in the distal arteries that are affected in this disorder.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015642     DOI: 10.1038/labinvest.2008.112

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  19 in total

Review 1.  ALK1 signaling in development and disease: new paradigms.

Authors:  Beth L Roman; Andrew P Hinck
Journal:  Cell Mol Life Sci       Date:  2017-09-04       Impact factor: 9.261

2.  Pulmonary hypertension in hereditary haemorrhagic telangiectasia.

Authors:  Veronique Mm Vorselaars; Sebastiaan Velthuis; Repke J Snijder; Jan Albert Vos; Johannes J Mager; Martijn C Post
Journal:  World J Cardiol       Date:  2015-05-26

3.  Endothelial GATA-6 deficiency promotes pulmonary arterial hypertension.

Authors:  Angela Ghatnekar; Izabela Chrobak; Charlie Reese; Lukasz Stawski; Francesca Seta; Elaine Wirrig; Jesus Paez-Cortez; Margaret Markiewicz; Yoshihide Asano; Russell Harley; Richard Silver; Carol Feghali-Bostwick; Maria Trojanowska
Journal:  Am J Pathol       Date:  2013-04-11       Impact factor: 4.307

4.  Functional analysis of saxophone, the Drosophila gene encoding the BMP type I receptor ortholog of human ALK1/ACVRL1 and ACVR1/ALK2.

Authors:  Vern Twombly; Erdem Bangi; Viet Le; Bettina Malnic; Matthew A Singer; Kristi A Wharton
Journal:  Genetics       Date:  2009-07-20       Impact factor: 4.562

5.  Vascular injury triggers Krüppel-like factor 6 mobilization and cooperation with specificity protein 1 to promote endothelial activation through upregulation of the activin receptor-like kinase 1 gene.

Authors:  Eva M Garrido-Martín; Francisco J Blanco; Mercé Roquè; Laura Novensà; Mirko Tarocchi; Ursula E Lang; Toru Suzuki; Scott L Friedman; Luisa M Botella; Carmelo Bernabéu
Journal:  Circ Res       Date:  2012-10-09       Impact factor: 17.367

6.  Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2.

Authors:  Juan Du; Yan Zhu; Yu-Lin Zhang; Sha Li; Jing Huang; Xiao-Hua Luo; Lin Liu
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

7.  Alk1 controls arterial endothelial cell migration in lumenized vessels.

Authors:  Elizabeth R Rochon; Prahlad G Menon; Beth L Roman
Journal:  Development       Date:  2016-06-10       Impact factor: 6.868

8.  Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells.

Authors:  Hongyu Tian; Karthikeyan Mythreye; Christelle Golzio; Nicholas Katsanis; Gerard C Blobe
Journal:  EMBO J       Date:  2012-08-31       Impact factor: 11.598

9.  ALK1 regulates the internalization of endoglin and the type III TGF-β receptor.

Authors:  Keren Tazat; Leslie Pomeraniec-Abudy; Melissa Hector-Greene; Szabina Szófia Szilágyi; Swati Sharma; Elise M Cai; Armando L Corona; Marcelo Ehrlich; Gerard C Blobe; Yoav I Henis
Journal:  Mol Biol Cell       Date:  2021-02-10       Impact factor: 4.138

10.  In Search of "Hepatic Factor": Lack of Evidence for ALK1 Ligands BMP9 and BMP10.

Authors:  Teresa L Capasso; Sara M Trucco; Morgan Hindes; Tristin Schwartze; Jamie L Bloch; Jacqueline Kreutzer; Stephen C Cook; Cynthia S Hinck; Davide Treggiari; Brian Feingold; Andrew P Hinck; Beth L Roman
Journal:  Am J Respir Crit Care Med       Date:  2021-01-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.